Hetero launches Favipiravir under brand name of Favivir in India, prices it at Rs 59 per tablet

Hyderabad: Pharma giant Hetero has announced the launch of generic Favipiravir in India under the brand name 'Favivir.'

Hetero has been granted the manufacturing and marketing approval for Favipiravir from the Drug Controller General of India (DCGI).

Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. It is an oral antiviral medication that has demonstrated positive clinical outcomes. Favivir improves treatment accessibility to a significant amount of Covid 19 patient population, which usually sustains mild to moderate symptoms.

Hetero's Favivir is priced at Rs. 59 per tablet and is marketed and distributed by Hetero Healthcare Limited. The product is available at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription. 

Backed by strong vertical integration capabilities, the drug is being manufactured at Hetero's world-class formulation facility in India, which has been approved by stringent global regulatory authorities such as USFDA and the EU, among others.

Hetero is one of India's leading generic pharmaceutical companies and the world's largest producer of antiretroviral drugs

The move by the company is line with the recent launches of cheaper versions of Favipiravir as compared to the one that was laucned by Glenmark earlier and was first priced at Rs 103 per tablet and later reduced to Rs 75 per tablet after objection from DCGI as well as others 

Medical dialogues had earlier reported about  The Drugs Control General of India (DCGI) nod to another two cheaper versions of Favipiravir. One manufactured by Brinton Pharmaceuticals while the other by Jenburkt Pharmaceuticals Ltd and were priced at Rs 59 and Rs 39 respectively.

Read also: DCGI nod to two cheaper favipiravir versions priced at Rs 59, Rs 39 per tablets

Read also: Cipla launches Cipremi at Rs 4,000 per vial